ArticleWorld journal of gastroenterology2015
Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement.
Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 121 citations in OpenAlex.
- Immunosuppressive-Therapy Management and Day-14 Molecular Remission in Ulcerative Colitis Complicated by Cytomegalovirus Colitis: An Exploratory Prospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Cytomegalovirus infection drives a distinct mucosal and systemic cytokine signature in ulcerative colitis.Virology journal · 2026Article
- Genetic proof of herpesviruses CMV, EBV and HHV-6 in intestinal biopsies from patients with inflammatory bowel diseases: prevalence and disease characteristics.Crohn's & colitis 360 · 2026Article
- Relationship between Epstein-Barr virus and inflammatory bowel disease.World journal of gastroenterology · 2025Review
- Human Cytomegalovirus and Epstein-Barr Virus Infection in Inflammatory Bowel Disease: Crossing the Diagnostic Barrier for Appropriate Management.Biomedicines · 2025Article
- Explainable ensemble learning for Epstein-Barr virus risk prediction in ulcerative colitis and Crohn's disease using routine biomarkers.Scientific reports · 2025Article
- Clinical characteristics and prognostic factors in patients with stool cytomegalovirus positivity.Journal of the Chinese Medical Association : JCMA · 2025Article
- Cytomegalovirus Detection by PCR on Fresh and Formalin-Fixed Colon Tissue Biopsies of Children with Colitis: A Prospective Cohort Study.Iranian journal of medical sciences · 2025Article
- Washed microbiota transplantation effectively treats a case of acute severe ulcerative colitis combined with viral myocarditis.Journal of biomedical research · 2025Article
- Diagnostic performance of noninvasive tests for cytomegalovirus ileocolitis: a systematic review and meta-analysis.Intestinal research · 2025Article
- Epstein-Barr virus infection exacerbates ulcerative colitis by driving macrophage pyroptosis via the upregulation of glycolysis.Precision clinical medicine · 2025Article
- Actively expressed microbiota in mucosal biopsies of treatment-naïve ulcerative colitis patients.Gut microbes reports · 2025Article
- Potential value and research frontiers of viruses in inflammatory bowel diseases: a bibliometric analysis.Frontiers in microbiology · 2025Article
- Beyond bacteria: Role of non-bacterial gut microbiota species in inflammatory bowel disease and colorectal cancer progression.World journal of gastroenterology · 2024Article
- Cytomegalovirus in Ulcerative Colitis: An Unwanted "Guest".Pathogens (Basel, Switzerland) · 2024Review
- Cytomegalovirus Infection in Adult Patients with Inflammatory Bowel Disease: A Literature Review.Archives of Iranian medicine · 2024Review
- Relationship between the risk of intestinal mucosal Epstein-Barr virus and/or cytomegalovirus infection and peripheral blood NK cells numbers in patients with ulcerative colitis: a cross-sectional study in Chinese population.Frontiers in microbiology · 2024Article
- Cytomegalovirus Infection: An Underrated Target in Inflammatory Bowel Disease Treatment.Journal of clinical medicine · 2023Review
- Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: an updated review.Archives of microbiology · 2023Review
- Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies.Open forum infectious diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the best diagnostic technique and risk factors of the human Cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) infection in inflammatory bowel disease (IBD).
methodsA cohort of 40 IBD patients (17 refractory) and 40 controls underwent peripheral blood and endoscopic colonic mucosal sample harvest. Viral infection was assessed by quantitative real-time polymerase chain reaction and immunohistochemistry, and correlations with clinical and endoscopic indexes of activity, and risk factors were investigated.
resultsAll refractory patients carried detectable levels of HCMV and/or EBV mucosal load as compared to 13/23 (56.5%) non-refractory and 13/40 (32.5%) controls. The median DNA value was significantly higher in refractory (HCMV 286 and EBV 5.440 copies/10(5) cells) than in non-refractory (HCMV 0 and EBV 6 copies/10(5) cells; P < 0.05 and < 0.001) IBD patients and controls (HCMV and EBV 0 copies/10(5) cells; P < 0.001 for both). Refractory patients showed DNA peak values ≥ 10(3) copies/10(5) cells in diseased mucosa in comparison to non-diseased mucosa (P < 0.0121 for HCMV and < 0.0004 for EBV), while non-refractory patients and controls invariably displayed levels below this threshold, thus allowing us to differentiate viral colitis from mucosal infection. Moreover, the mucosal load positively correlated with the values found in the peripheral blood, whilst no correlation with the number of positive cells at immunohistochemistry was found. Steroid use was identified as a significant risk factor for both HCMV (P = 0.018) and EBV (P = 0.002) colitis. Finally, a course of specific antiviral therapy with ganciclovir was successful in all refractory patients with HCMV colitis, whilst refractory patients with EBV colitis did not show any improvement despite steroid tapering and discontinuation of the other medications.
conclusionViral colitis appeared to contribute to mucosal lesions in refractory IBD, and its correct diagnosis and management require quantitative real-time polymerase chain reaction assay of mucosal specimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.